small sized icon representing the Cardiovascular area of interest
Cardiovascular
medium sized icon representing the Diabetes Care area of interest
Diabetes Care
small sized icon representing the Radiology area of interest
Radiology
small sized icon representing the Oncology area of interest
Oncology
small sized icon representing the Ophthalmology area of interest
Ophthalmology
small sized icon representing the Women's Health area of interest
Women's Health
medium sized icon representing the Nephrology area of interest
Nephrology
Bayer MedLearnEducate, Innovate & Heal
- EYLEA General -
- nAMD -
- DMO –

TRUST THE EYLEA EXPERIENCE

EYLEA 2 mg is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).[1]

 

The tried-and-trusted EYLEA molecule is supported by extensive evidence in both pivotal trials and clinical practice.[1][2]

Abbreviations

DMO, diabetic macular oedema. mCNV, myopic choroidal neovascularisation. MoA, mechanism of action. nAMD, neovascular age-related macular degeneration. R&D, research and development. RVO, retinal vein occlusion. VEGF, vascular endothelial growth factor.

 

 

 

PP-EYL-GB-2336 | August 2024

Next Page
Safety Profile
    • 1
      EYLEA® 40 mg/mL Summary of Product Characteristics.
    • 2
      Bayer. Data on File. EYLO020.
    • 3
      Papadopoulos N, et al. Angiogenesis 2012;15:171–185.
    • 4
      Kanda A, et al. Sci Rep 2015;5:17946.
    • 5
      Amadio M, et al. Pharmacol Res 2016;103:253–269.
    • 6
      EMA. EYLEA EPAR assessment report 2012. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/eylea. Accessed: August 2024.
    • 7
      Fauser S & Muether PS. Br J Ophthalmol 2016;100:1494–1498.